CRSPHIGH SIGNALFINANCIAL10-K

CRSP shows severely deteriorating financial performance with operating cash flow burning 142% more cash despite revenue growth, while net losses widened 59% to $582M.

The massive increase in cash burn despite higher revenues indicates significant operational inefficiencies and unsustainable spending patterns that could threaten the company's ability to fund operations. While cash reserves increased to $348M, the accelerating burn rate of $345M annually suggests potential liquidity concerns within 12 months if trends continue.

Comparing 2026-02-12 vs 2025-02-11View on EDGAR →
FINANCIAL ANALYSIS

Despite revenue growing 37% to $290M, CRSP's financial health deteriorated dramatically with net losses expanding 59% to $582M and operating cash burn more than doubling to $345M. Current liabilities surged 70% to $149M while R&D expenses only declined 11%, indicating poor cost management relative to the increased spending elsewhere. The combination of accelerating losses, massive cash burn, and rising short-term obligations creates a concerning financial trajectory that threatens near-term sustainability despite modest cash position improvements.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-141.7%
-$142.8M-$345.0M

Operating cash flow fell 141.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
+69.9%
$87.8M$149.1M

Current liabilities surged 69.9% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-58.8%
-$366.3M-$581.6M

Net income declined 58.8% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
-51.9%
$1.9M$914K

Capex reduced 51.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-42.4%
-$466.6M-$664.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+36.6%
$211.9M$289.6M

Strong top-line growth of 36.6% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
+16.5%
$298.3M$347.6M

Cash grew 16.5% — improving liquidity position supports investment and shareholder returns.

R&D Expense
P&L
-11.2%
$320.7M$284.8M

R&D spending cut 11.2% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
+10.8%
$310.0M$343.4M

Liabilities increased 10.8% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-11
ADDED
The number of the Registrant s common shares outstanding as of February 10, 2026 was 95,985,312 .
CRISPR Therapeutics standard character mark and design logo, CRISPRX , CRISPR TX , CTX112 , CTX211 , CTX213 , CTX310 , CTX321 , CTX340 , CTX460 , CTX611 and SyNTase are trademarks and registered trademarks of CRISPR Therapeutics AG.
governmental agencies, new or increased international tariffs and retaliatory tariffs, interest rate and currency rate fluctuations, new laws and regulations or amendments to existing laws and regulations in the U.S.
and foreign countries, trade protection measures, economic sanctions and economic slowdowns or recessions, banking instability, monetary policy changes, geopolitical tensions or the outbreak of hostilities or war.
We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology.
+7 more — sign up free →
REMOVED
The number of the Registrant s common shares outstanding as of February 7, 2025 was 85,774,474 .
CRISPR Therapeutics standard character mark and design logo, CRISPRX TM , CRISPR TX TM , CTX112 TM , CTX131 TM , CTX211 TM , CTX213 TM , CTX310 TM , CTX320 TM , CTX330 TM , CTX340 TM , and CTX450 TM , are trademarks and registered trademarks of CRISPR Therapeutics AG.
We are a leading gene editing company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology.
We aim to apply this technology to disrupt, delete, correct and insert genes to treat genetic diseases and to engineer advanced cellular therapies.
The use of CRISPR/Cas9 for gene editing was co-invented by one of our scientific founders, Dr.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →